JP2024540085A5 - - Google Patents
Info
- Publication number
- JP2024540085A5 JP2024540085A5 JP2024525344A JP2024525344A JP2024540085A5 JP 2024540085 A5 JP2024540085 A5 JP 2024540085A5 JP 2024525344 A JP2024525344 A JP 2024525344A JP 2024525344 A JP2024525344 A JP 2024525344A JP 2024540085 A5 JP2024540085 A5 JP 2024540085A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- item
- coding sequence
- protein
- protein coding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272324P | 2021-10-27 | 2021-10-27 | |
| US63/272,324 | 2021-10-27 | ||
| US202263306037P | 2022-02-02 | 2022-02-02 | |
| US63/306,037 | 2022-02-02 | ||
| US202263369864P | 2022-07-29 | 2022-07-29 | |
| US63/369,864 | 2022-07-29 | ||
| PCT/US2022/078798 WO2023077012A1 (en) | 2021-10-27 | 2022-10-27 | Compositions and methods for expressing factor ix for hemophilia b therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540085A JP2024540085A (ja) | 2024-10-31 |
| JP2024540085A5 true JP2024540085A5 (cg-RX-API-DMAC7.html) | 2025-10-30 |
Family
ID=84439883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525344A Pending JP2024540085A (ja) | 2021-10-27 | 2022-10-27 | 血友病b療法のための第ix因子を発現させるための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230149563A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4423119A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540085A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099358A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022379633A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232470A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024001251A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024005281A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312000A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005124A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202334194A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023077012A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024315073A1 (en) * | 2023-07-28 | 2026-01-22 | Regeneron Pharmaceuticals, Inc. | Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025265017A1 (en) * | 2024-06-20 | 2025-12-26 | Regeneron Pharmaceuticals, Inc. | Ass1 gene insertion for the treatment of citrullinemia type i |
| WO2026100298A1 (ja) * | 2024-11-06 | 2026-05-15 | 学校法人自治医科大学 | ポリヌクレオチド、ベクター、血友病b治療用組成物、脂質ナノ粒子、細胞生成方法、及び血友病b治療方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE347593T1 (de) | 2002-01-23 | 2006-12-15 | Univ Utah Res Found | Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen |
| EP1504092B2 (en) | 2002-03-21 | 2014-06-25 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US9447434B2 (en) | 2002-09-05 | 2016-09-20 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| KR20070060115A (ko) | 2004-09-16 | 2007-06-12 | 상가모 바이오사이언스 인코포레이티드 | 단백질 생산을 위한 조성물 및 방법 |
| EP2027262B1 (en) | 2006-05-25 | 2010-03-31 | Sangamo Biosciences Inc. | Variant foki cleavage half-domains |
| US7951925B2 (en) | 2006-05-25 | 2011-05-31 | Sangamo Biosciences, Inc. | Methods and compositions for gene inactivation |
| EP2108045B1 (en) | 2007-02-01 | 2013-12-11 | Baxter International Inc. | Improved fix-mutant proteins for hemophilia b treatment |
| US8022187B2 (en) | 2007-02-01 | 2011-09-20 | Baxter International Inc. | FVIII-independent FIX-mutant proteins for hemophilia A treatment |
| US8110379B2 (en) | 2007-04-26 | 2012-02-07 | Sangamo Biosciences, Inc. | Targeted integration into the PPP1R12C locus |
| CA2720903C (en) | 2008-04-14 | 2019-01-15 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| EP2149603A1 (en) | 2008-07-28 | 2010-02-03 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders |
| JP5908725B2 (ja) | 2008-08-22 | 2016-04-26 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 標的一本鎖開裂および標的組込みのための方法、並びに組成物 |
| US9255259B2 (en) | 2010-02-09 | 2016-02-09 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| US9567573B2 (en) | 2010-04-26 | 2017-02-14 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using nucleases |
| AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
| EP2758529B1 (en) | 2011-09-21 | 2019-03-20 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of transgene expression |
| US9222105B2 (en) | 2011-10-27 | 2015-12-29 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the HPRT locus |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| EP2881463A1 (en) | 2013-12-09 | 2015-06-10 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders |
| CA3229275A1 (en) * | 2013-12-09 | 2015-06-18 | Sangamo Biosciences, Inc. | Methods and compositions for genome engineering |
| EP4378487A3 (en) * | 2015-06-23 | 2024-09-04 | The Children's Hospital of Philadelphia | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues |
| TWI753168B (zh) * | 2017-05-22 | 2022-01-21 | 日商武田藥品工業股份有限公司 | 用於血友病b基因療法之編碼具有增強表現的重組fix變異體之病毒載體 |
| JP7119009B2 (ja) * | 2017-05-31 | 2022-08-16 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 最適化されたヒト凝固第ix因子遺伝子発現カセットおよびそれらの使用 |
| AU2019323747A1 (en) * | 2018-08-20 | 2021-03-04 | Ucl Business Ltd | Factor ix encoding nucleotides |
| CN113272428A (zh) | 2018-10-18 | 2021-08-17 | 英特利亚治疗股份有限公司 | 核酸构建体和使用方法 |
| JP7578590B2 (ja) | 2018-10-18 | 2024-11-06 | インテリア セラピューティクス,インコーポレーテッド | 第ix因子を発現するための組成物及び方法 |
| BR112021007343A2 (pt) | 2018-10-18 | 2021-08-03 | Intellia Therapeutics, Inc. | composições e métodos para expressão de transgene a partir de um lócus de albumina |
| WO2020160303A1 (en) * | 2019-02-01 | 2020-08-06 | Baxalta Incorporated | Gene therapy of hemophilia b using viral vectors encoding recombinant fix variants with increased expression |
| ES3062513T3 (en) * | 2019-03-19 | 2026-04-13 | CSL Innovation Pty Ltd | Factor ix variants and uses thereof in therapy |
-
2022
- 2022-10-27 KR KR1020247017650A patent/KR20240099358A/ko active Pending
- 2022-10-27 JP JP2024525344A patent/JP2024540085A/ja active Pending
- 2022-10-27 IL IL312000A patent/IL312000A/en unknown
- 2022-10-27 TW TW111140939A patent/TW202334194A/zh unknown
- 2022-10-27 CA CA3232470A patent/CA3232470A1/en active Pending
- 2022-10-27 WO PCT/US2022/078798 patent/WO2023077012A1/en not_active Ceased
- 2022-10-27 MX MX2024005124A patent/MX2024005124A/es unknown
- 2022-10-27 AU AU2022379633A patent/AU2022379633A1/en active Pending
- 2022-10-27 EP EP22818964.3A patent/EP4423119A1/en active Pending
- 2022-10-27 US US18/050,161 patent/US20230149563A1/en active Pending
-
2024
- 2024-04-22 CL CL2024001251A patent/CL2024001251A1/es unknown
- 2024-04-25 CO CONC2024/0005281A patent/CO2024005281A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12234449B2 (en) | CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10) | |
| EP3368560B1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| US20260125677A1 (en) | Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency | |
| JP2025508677A5 (cg-RX-API-DMAC7.html) | ||
| JP6642943B2 (ja) | 血友病を処置するための方法および組成物 | |
| EP3180022B1 (en) | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders | |
| JP7473548B2 (ja) | Mmaの処置のための非破壊的遺伝子治療 | |
| CA3017956A1 (en) | Crispr/cas-related methods and compositions for treating beta hemoglobinopathies | |
| WO2015157070A2 (en) | Crispr/cas-related methods and compositions for treating cystic fibrosis | |
| WO2015153780A1 (en) | Crispr/cas-related methods and compositions for treating primary open angle glaucoma | |
| US20230149563A1 (en) | Compositions and methods for expressing factor ix for hemophilia b therapy | |
| Ohmori et al. | New approaches to gene and cell therapy for hemophilia | |
| JP2020527030A (ja) | 肝臓において目的のタンパク質を発現するためのプラットフォーム | |
| JP2022553573A5 (cg-RX-API-DMAC7.html) | ||
| CA3108376A1 (en) | Compositions and methods for treating cep290-associated disease | |
| US11634726B2 (en) | Cas9 nucleic acid molecules and their use | |
| JP2025514304A5 (cg-RX-API-DMAC7.html) | ||
| KR102847166B1 (ko) | 항응고 인자들의 유전자 에디팅 | |
| CN112041437A (zh) | 用于恢复f8基因功能的腺相关病毒组合物和其使用方法 | |
| US20230190889A1 (en) | Gene editing of anticoagulant factors | |
| CN117980482A (zh) | Rbm20突变的基因组编辑 | |
| US20200263204A1 (en) | Composition for treating hemophilia a by crispr/cas system of reverting fviii gene inversion | |
| US20260002151A1 (en) | Compositions and methods for the modification and regulation of liver gene expression | |
| US20240325454A1 (en) | Genomic editing of rbm20 mutations | |
| AU779514B2 (en) | Methods and compositions for use in gene therapy for treatment of hemophilia |